11:52 AM EDT, 05/09/2024 (MT Newswires) -- X4 Pharmaceuticals ( XFOR ) said Thursday it has received a total of $125 million in additional capital, extending its projected cash runway into late 2025.

The company said it raised $105 million after completing the sale of its rare pediatric disease priority review voucher to an undisclosed buyer and drew an additional tranche of $20 million under its existing term loan facility with Hercules Capital.

These transactions resulted from the US Food and Drug Administration's approval of Xolremdi to treat WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome, according to the company.

X4 shares were up 6.7% in recent trading.

Price: 1.11, Change: +0.07, Percent Change: +6.73